Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anna Barcellos"'
Autor:
Curtis Lachowiez, Christina Zettler, Anna Barcellos, Andrew Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Ronan Swords
Publikováno v:
HemaSphere, Vol 7, p e321757d (2023)
Externí odkaz:
https://doaj.org/article/9fff253f28a048dabd3fceb03ae3db9a
Autor:
Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, Christina M. Zettler, Ching-Kun Wang
Publikováno v:
Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100742- (2023)
Introduction/ Background: Surgical resection remains standard of care for patients with early-stage non-small cell lung cancer (NSCLC), but research shows that adjuvant therapy can reduce the risk of disease recurrence. Our objective was to character
Externí odkaz:
https://doaj.org/article/933944f54c9040df8d044d4ec368b8f6
Autor:
Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, Ching-Kun Wang
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-106
Autor:
Dianne Pulte, Kelly J. Norsworthy, Laura Fernandes, Bindu Kanapuru, Catherine Lerro, Fatima Rizvi, Jonathon Vallejo, Kun Wang, Joseph Wynne, Anna Barcellos, Andrew J. Belli, Eric Hansen, Thomas Gwise, Paul Kluetz, Angelo De Claro, Ching-Kun Wang, Donna Rivera
Publikováno v:
Blood. 140:5100-5102
Autor:
William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr
Publikováno v:
Blood. 140:4142-4143
Autor:
Vishal Bhatnagar, Bindu Kanapuru, Laura Fernandes, Ting-Yu Chen, Mallorie H. Fiero, Erica Horodniceanu, Nicole Gormley, Catherine Lerro, Fatima Rizvi, Yuan-Li Shen, Felice Yang, Anna Barcellos, Andrew J. Belli, Eric Hansen, Ching-Kun Wang, Donna Rivera, Paul Kluetz
Publikováno v:
Blood. 140:7156-7157
Autor:
Reetu Mukherji, Chao Yin, Benjamin Adam Weinberg, Ali Alqahtani, Rumaisa Hameed, Anna Barcellos, Maegan Connole, Chelsea Perelgut, Josephine Fortuin, John Marshall
Publikováno v:
Journal of Clinical Oncology. 41:789-789
789 Background: Cape is an oral fluoropyrimidine (FP) used as maint therapy in CRC and PC. While the standard FDA dosing is 1250 mg/m2 twice daily (BID) for 14 days followed by 7 days off in a 21-day cycle, there are variations across institutions as